Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 15;13:39. doi: 10.1186/s12974-016-0499-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Hines-Beard et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Treatment with rAAV.EpoR76E at 5 months protects against vision loss at 6 and 8 months of age. a Graph of hematocrit level over time in mice after systemic injection of rAAV.EpoR76E compared to baseline levels in rAAV.eGFP-injected mice (line) showing a statistically significant increase at 4 and 12 weeks. b Graph of IOP level over time showing a statistically significant increase by 5.5 months of age in both rAAV.eGFP- and rAAV.EpoR76E-treated mice as compared to levels at 3 months of age. There was no difference between treatment groups at any time-point. Arrow indicates when an increase in hematocrit was first detected after gene delivery of EpoR76E. c–e Representative SC fluorescence heat maps of (c) 3-month-old mice, (d) 8-month-old mice treated with rAAV.eGFP, and (e) 8-month-old mice treated with rAAV.EpoR76E. Orientation labels in (c) apply to all heat maps. f Scatter plot of percent axon transport to the SC. The red circle indicates optic nerves with poor axon transport, note the lack of nerves with poor transport in the rAAV.EpoR76E-treated cohort, p < 0.0001 by Bartlett’s test. g Box and whisker plots of fVEP N1 peak amplitude shown as absolute values. h Box and whisker plots of fVEP P1 peak amplitude. The amplitudes in the rAAV.eGFP-treated mice were decreased as compared to 3-month-old controls. There was no statistically significant difference between the rAAV.EpoR76E-treated mice and either other group. *p < 0.05, **p < 0.01, ***p < 0.001, and ^# p < 0.0001